A long-term extension study to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in participants of previous amlitelimab clinical trials in moderate to severe atopic dermatitis.

drug protocol number
LTS17367
drug sponsor
Sanofi / Arab Med
drug study
SAR445229 (Amlitelimab)
drug trial site
King Faisal Specialist Hospital and Research Center (Riyadh)
drug status
Ongoing
drug phase